Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback